Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | serine/threonine protein kinase | 0.2591 | 1 | 1 |
Trypanosoma brucei | cdc2-related kinase 1 | 0.058 | 0 | 0.5 |
Trypanosoma cruzi | cdc2-related kinase 3 | 0.058 | 0 | 0.5 |
Plasmodium falciparum | protein kinase 5 | 0.058 | 0 | 0.5 |
Echinococcus granulosus | MAP kinase activated protein kinase 2 | 0.2591 | 1 | 1 |
Entamoeba histolytica | cell division protein kinase 2, putative | 0.058 | 0 | 0.5 |
Trypanosoma cruzi | cdc2-related kinase 3 | 0.058 | 0 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.058 | 0 | 0.5 |
Plasmodium vivax | protein kinase Crk2 | 0.058 | 0 | 0.5 |
Trypanosoma cruzi | cdc2-related kinase 1 | 0.058 | 0 | 0.5 |
Loa Loa (eye worm) | camk/mapkapk/mapkapk protein kinase | 0.2591 | 1 | 1 |
Giardia lamblia | Kinase, CMGC CDK | 0.058 | 0 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.058 | 0 | 0.5 |
Giardia lamblia | Kinase, CMGC CDK | 0.058 | 0 | 0.5 |
Entamoeba histolytica | cell division protein kinase 2, putative | 0.058 | 0 | 0.5 |
Trypanosoma cruzi | cdc2-related kinase 1 | 0.058 | 0 | 0.5 |
Toxoplasma gondii | cell-cycle-associated protein kinase CDK, putative | 0.058 | 0 | 0.5 |
Echinococcus multilocularis | MAP kinase activated protein kinase 2 | 0.2591 | 1 | 1 |
Trypanosoma brucei | cdc2-related kinase 3 | 0.058 | 0 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.058 | 0 | 0.5 |
Leishmania major | cell division related protein kinase 2,cdc2-related kinase | 0.058 | 0 | 0.5 |
Leishmania major | cell division protein kinase 2,cdc2-related kinase | 0.058 | 0 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.